Jasper Therapeutics, Inc.
Business
Jasper Therapeutics is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting the SCF/KIT pathway to deplete mast cells in mast-cell-driven diseases. The company is advancing briquilimab in Phase 1b/2a trials for chronic spontaneous urticaria and Phase 1b in asthma, with positive preliminary efficacy and safety data. Jasper holds exclusive worldwide license agreements with Amgen for briquilimab development and with Stanford University for hematopoietic stem cell transplantation conditioning.
Summary from 10-K filed 2026-03-30
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 63 | 56 | 52 | 35 | 25 | |
| General and administrative | 21 | 20 | 17 | 17 | 11 | |
| Total operating expenses | 84 | 76 | 69 | 51 | 37 | |
| Loss from operations | −84 | −76 | −69 | −51 | −37 | |
| Interest income | 2 | 5 | 5 | 701,000 | — | |
| Change in fair value of warrant liability | 9 | — | −575,000 | 7 | 500,000 | |
| Other expense, net | −2 | −88,000 | −246,000 | 586,000 | −80,000 | |
| Total other income, net | 8 | 5 | 4 | — | — | |
| Net loss and comprehensive loss | −76 | −71 | −65 | −38 | −31 | |
| Net loss per share attributable to common stockholders, basic (in Dollars per share) | −3.95 | −4.89 | −6.18 | −10.33 | −2.69 | |
| Net loss per share attributable to common stockholders, diluted (in Dollars per share) | −3.95 | −4.89 | −6.18 | −10.33 | −2.69 | |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in Shares) | 19 | 15 | 10 | 4 | 11 | |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in Shares) | 19 | 15 | 10 | 4 | 11 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 29 | 72 | 87 | 38 | 85 | |
| Prepaid expenses and other current assets | 6 | 4 | 2 | 3 | 3 | |
| Total current assets | 35 | 76 | 89 | 42 | 88 | |
| Property and equipment, net | 102,000 | 2 | 3 | 4 | 4 | |
| Operating lease right-of-use assets | 502,000 | 976,000 | 1 | 2 | 1 | |
| Restricted cash | 417,000 | 417,000 | 417,000 | 417,000 | 345,000 | |
| Other non-current assets | 113,000 | 820,000 | 1 | 759,000 | 645,000 | |
| Total assets | 36 | 80 | 95 | 48 | 94 | |
| Accounts payable | 6 | 4 | 4 | 2 | 4 | |
| Current portion of operating lease liabilities | 1 | 1 | 972,000 | 865,000 | 505,000 | |
| Accrued expenses and other current liabilities | 6 | 10 | 7 | 4 | 4 | |
| Total current liabilities | 13 | 15 | 12 | 7 | 8 | |
| Non-current portion of operating lease liabilities | — | 724,000 | 2 | 3 | 2 | |
| Warrant liability | 16 | — | — | 150,000 | — | |
| Other non-current liabilities | 2 | 2 | 2 | 2 | 643,000 | |
| Total liabilities | 32 | 18 | 16 | 12 | 24 | |
| Commitments and contingencies (Note 8) | — | — | — | — | — | |
| Preferred stock: $0.0001 par value 10,000,000 shares authorized at December 31, 2025 and 2024; none issued and outstanding at December 31, 2025 and 2024 | — | — | — | — | — | |
| Common stock: $0.0001 par value 492,000,000 shares authorized at December 31, 2025 and 2024; 27,996,819 and 15,022,122 shares issued and outstanding at December 31, 2025 and 2024, respectively | 3,000 | 2,000 | 1,000 | — | 4,000 | |
| Additional paid-in capital | 321 | 303 | 248 | 141 | 137 | |
| Accumulated deficit | −317 | −241 | −170 | −105 | −67 | |
| Total stockholders equity | 4 | 62 | 78 | 36 | 70 | |
| Total liabilities and stockholders equity | 36 | 80 | 95 | 48 | 94 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization expense | 1 | 1 | 1 | 975,000 | 377,000 | |
| Impairment of long-lived assets | 1 | — | — | — | — | |
| Non-cash lease expense | 1 | 491,000 | 419,000 | — | — | |
| Stock-based compensation expense | 7 | 7 | 5 | 4 | 1 | |
| Offering costs recognized in other expense, net | 2 | — | — | — | — | |
| Prepaid expenses and other current assets | −2 | −2 | 767,000 | 312,000 | −2 | |
| Other non-current assets | 707,000 | 523,000 | −584,000 | −114,000 | −347,000 | |
| Accounts payable | 2 | −122,000 | 2 | −2 | 3 | |
| Accrued expenses and other current liabilities | −4 | 3 | 3 | 836,000 | 959,000 | |
| Operating lease liability | −2 | −973,000 | −865,000 | −589,000 | −117,000 | |
| Net cash used in operating activities | −77 | −63 | −52 | −46 | −34 | |
| Purchases of property and equipment | −7,000 | −552,000 | −267,000 | −576,000 | −2 | |
| Proceeds from sales of property and equipment | 12,000 | 20,000 | — | — | — | |
| Net cash provided by (used in) investing activities | 5,000 | −532,000 | −267,000 | −576,000 | −2 | |
| Proceeds from issuance of common stock through ATM offering, net | 6 | — | 101 | 28,000 | — | |
| Proceeds from issuance of common stock and warrants through underwritten offering, net | 28 | 47 | — | — | — | |
| Proceeds from exercise of common stock options | — | 329,000 | 388,000 | 27,000 | 235,000 | |
| Proceeds from issuance of common stock pursuant to Employee Stock Purchase Plan | 243,000 | 360,000 | — | — | — | |
| Net cash provided by financing activities | 34 | 48 | 101 | 55,000 | 101 | |
| Net decrease in cash, cash equivalents and restricted cash | −43 | −15 | 49 | −46 | 65 | |
| Right-of-use asset obtained in exchange for lease liabilities | 1 | — | — | 1 | — | |
| Warrant liability recognized in connection with underwritten offering | 25 | — | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Jasper Therapeutics, Inc.'s CIK number?
Jasper Therapeutics, Inc.'s SEC CIK number is 0001788028 (1788028). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Jasper Therapeutics, Inc.'s SEC filings?
All of Jasper Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Jasper Therapeutics, Inc. last report earnings?
Jasper Therapeutics, Inc. (JSPR) most recently filed an earnings 8-K with the SEC on May 14, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001213900-26-056596). This is Jasper Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Jasper Therapeutics, Inc.'s most recent earnings 8-K?
Jasper Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 14, 2026 under accession 0001213900-26-056596. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Jasper Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →